Kinzalkomb (Hydrochlorothiazide, Telmisartan)

Hydrochlorothiazide acts on the distal convoluted tubule of the kidney to inhibit sodium‑chloride reabsorption, promoting diuresis and decreasing plasma volume. Telmisartan selectively blocks the AT1 receptor for angiotensin II, preventing vasoconstriction, aldosterone release and sympathetic activation. Together they lower peripheral resistance and circulating fluid, resulting in a synergistic reduction of systolic and diastolic blood pressure.

The dose of Kinzalkomb is individualized by the prescribing clinician based on the patient’s blood‑pressure level, response to therapy, renal function, and any concomitant medications. The prescriber selects the appropriate tablet strength and titrates as needed to achieve target blood‑pressure goals while monitoring for safety. No fixed dosing regimen is provided here.

Safety data for Kinzalkomb in pregnancy are limited, and the combination is generally avoided unless the potential benefit justifies the risk to the fetus. It is classified as contraindicated in the second and third trimesters because of potential fetal toxicity. Breastfeeding is not recommended unless the prescriber determines that the benefit to the mother outweighs possible risks to the infant.

To request Kinzalkomb, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with monotherapy agents, Kinzalkomb offers the convenience of a single tablet that addresses two complementary mechanisms—volume reduction and angiotensin II blockade—often resulting in better blood‑pressure control than either component alone. It may be preferred over separate prescriptions for a thiazide diuretic and an ARB, reducing pill burden and improving adherence, while maintaining a safety profile similar to its individual ingredients.

Kinzalkomb tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original container, protect it from moisture, excessive heat and direct sunlight. Do not store in the bathroom or near a kitchen sink. Ensure that the tablets are kept out of reach of children and pets.

Kinzalkomb is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional. The tablet should be swallowed whole with a full glass of water. Patients should follow the prescriber’s instructions regarding timing, especially if other antihypertensive agents are used, and should not split, crush or chew the tablet unless specifically advised.

The most serious adverse events to monitor include severe hypotension, which can cause dizziness or fainting; acute kidney injury, especially in patients with pre‑existing renal impairment; hyperkalemia, a potentially life‑threatening elevation of potassium; and severe allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these symptoms occur, and regular laboratory monitoring is advised during therapy.

Kinzalkomb is contraindicated in patients with known hypersensitivity to either hydrochlorothiazide or telmisartan, in those with severe hepatic impairment, and in pregnant women during the second and third trimesters. It should also be avoided in individuals with severe renal artery stenosis or those taking concomitant medications that could cause dangerous hyperkalemia, such as potassium‑sparing diuretics, unless closely supervised by a physician.